Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">PTC Therapeutics downgrade details — to Equal Weight at Barclays; tgt lowered to $13 (10.46 -0.12)Barclays downgrades PTCT to Equal Weight from Overweight and lowers their tgt to $13 from $20 following the failure of the ACT CF trial. PTC announced that the confirmatory trial of ataluren did not hit on the primary or secondary endpoints — effectively ending the development program of ataluren in nmCF. While firm and investors had low confidence in the program, today's failure nonetheless eliminates an area of expansion for the ataluren program. <strong>Looking ahead firm sees limited upside to PTCT shares</strong>, as 1) US approval in nmDMD is unlikely, 2) EU sales of Translarna are well characterized and fairly valued at current levels, and 3) other pipeline programs are early, with limited catalysts over the next 12 months. In speaking with the company, management remains focused on the EU confirmatory trial and commercial expansion of Translarna OUS in nmDMD. While there are still some potential opportunities for upside surprise (e.g., US approval), they see better risk/reward opportunity among other SMid cap biotech names.</td> </tr></table>"